Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 23;24(7):6039.
doi: 10.3390/ijms24076039.

Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control

Affiliations
Review

Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control

Mahmoud E Youssef et al. Int J Mol Sci. .

Abstract

The number of diabetic patients has risen dramatically in recent decades, owing mostly to the rising incidence of type 2 diabetes mellitus (T2DM). Several oral antidiabetic medications are used for the treatment of T2DM including, α-glucosidases inhibitors, biguanides, sulfonylureas, meglitinides, GLP-1 receptor agonists, PPAR-γ agonists, DDP4 inhibitors, and SGLT2 inhibitors. In this review we focus on the possible effects of SGLT2 inhibitors on different body systems. Beyond the diabetic state, SGLT2 inhibitors have revealed a demonstrable ability to ameliorate cardiac remodeling, enhance myocardial function, and lower heart failure mortality. Additionally, SGLT2 inhibitors can modify adipocytes and their production of cytokines, such as adipokines and adiponectin, which enhances insulin sensitivity and delays diabetes onset. On the other hand, SGLT2 inhibitors have been linked to decreased total hip bone mineral deposition and increased hip bone resorption in T2DM patients. More data are needed to evaluate the role of SGLT2 inhibitors on cancer. Finally, the effects of SGLT2 inhibitors on neuroprotection appear to be both direct and indirect, according to scientific investigations utilizing various experimental models. SGLT2 inhibitors improve vascular tone, elasticity, and contractility by reducing oxidative stress, inflammation, insulin signaling pathways, and endothelial cell proliferation. They also improve brain function, synaptic plasticity, acetylcholinesterase activity, and reduce amyloid plaque formation, as well as regulation of the mTOR pathway in the brain, which reduces brain damage and cognitive decline.

Keywords: SGLT2 inhibitors; bone minerals; cancer; cardiorenal effects; cardiovascular effects; cognitive effects; metabolism.

PubMed Disclaimer

Conflict of interest statement

There is no conflict of interest.

Figures

Figure 1
Figure 1
Mechanism of action of SGLT2 inhibitors.
Figure 2
Figure 2
Cardiac effects of SGLT2 inhibitors.
Figure 3
Figure 3
Effect of SGLT2 inhibitors on adipose tissue.
Figure 4
Figure 4
Anticancer effects of SGLT2 inhibitors.
Figure 5
Figure 5
Mechanism of SGLT2 inhibitors on bone metabolism.

Similar articles

Cited by

References

    1. Kelly S.J., Ismail M. Stress and type 2 diabetes: A review of how stress contributes to the development of type 2 diabetes. Annu. Rev. Public Health. 2015;36:441–462. doi: 10.1146/annurev-publhealth-031914-122921. - DOI - PubMed
    1. Ahmadieh H., Sawaya M.-T., Azar S.T. Management and control of type 2 diabetes mellitus in Lebanon: Results from the International Diabetes Management Practices Study Wave 6. World J. Diabetes. 2019;10:249. doi: 10.4239/wjd.v10.i4.249. - DOI - PMC - PubMed
    1. Eyre H., Kahn R., Robertson R.M., ACS/ADA/AHA Collaborative Writing Committee. ACS/ADA/AHA Collaborative Writing Committee Members. Clark N.G., Doyle C., Hong Y., Gansler T., Glynn T. Preventing cancer, cardiovascular disease, and diabetes: A common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation. 2004;109:3244–3255. doi: 10.1161/01.CIR.0000133321.00456.00. - DOI - PubMed
    1. Campbell-Tofte J.I., Mølgaard P., Winther K. Harnessing the potential clinical use of medicinal plants as anti-diabetic agents. Bot. Targets Ther. 2012;2:7–19. doi: 10.2147/BTAT.S17302. - DOI
    1. Yaribeygi H., Katsiki N., Behnam B., Iranpanah H., Sahebkar A. MicroRNAs and type 2 diabetes mellitus: Molecular mechanisms and the effect of antidiabetic drug treatment. Metabolism. 2018;87:48–55. doi: 10.1016/j.metabol.2018.07.001. - DOI - PubMed

MeSH terms

Substances